Member Info for roger65

With regards to underestimating Tim, I’ve often done exactly that and never been disappointed. It’s when I believe any of his promises that I come away feeling let down.

Anyway, if what you say is true about a ‘reversion clause’ then I wish Tim had sorted that out before the patent was filed and he blabbed about there being a deal by year end or even ‘any day from now’. If rights could revert to IMM that would be excellent news but my gut tells me Avion aren’t going to quietly sit and watch this opportunity pass them by without making a decent amount of cash for themselves.

Mind you, it’s worth noting that Avion is owned by Alora and they are only valued at about £20m? If that’s correct then I guess it’s not beyond the bounds of possibility a big pharma scoops up IMM, Avion and Alora too in a deal worth a few hundred million quid?

Avion have indeed played an absolute blinder here. How much did they pay as an upfront payment for the initial agreement? £120k? Promises to pay more for phase 3 trials, royalties and milestone payments. Of course not a cent has been paid but they now have IMM over a barrel with regards any potential deal. Tim has of course conveniently brushed over this by er not saying a word. It seriously impairs IMM’s negotiating position and Avion can apply as much pressure as they wish to extract what ever they want, either cash or even a share of royalties etc going forward without having to pay the final trial costs. Going to be very interesting - amusing - to see how Tim presents this to share holders. Having done such a shocker of a deal before that has led to nothing, does anyone really have that much ‘faith’ in him to sit down with a major pharma and get a good deal for IMM share holders? Answers on a postcard

? Not sure about that. Can’t remember the last time there were more than even just 10 trades in a day. That kind of volume won’t do anything and means nothing.

Well at least you’re realistic about the chances here. Given the track record of the Directors though I’m highly sceptical

Precisely nolopus, Tim has repeatedly given interviews and not made any mention of Avion. Why is that? Because he wants to present too much Rosie a picture than actually is the case in my view but I’ve already come to the conclusion you can’t trust this guy and I know there will be others who will jump to his defence.

Well that certainly deflates Tim’s balloon of optimism rather considerably for a massive deal in my opinion.Sole rights for P140 in the states will mean a huge chunk of any deal will go to Avion and not IMM

Could a deal even be struck between a major pharmaceutical company and Avion and leave IMM out of the picture altogether? Why not just go straight to Avion and buy their exclusive rights to the US market for P1 14?

Boom or bust in short order is definitely not an investment! It is exactly what you would expect on AIM and that is a role of the dice. Place your bets.

There really doesn’t appear to be any sense of urgency or a sense that there’s anything ‘critical’ about these minerals. Publishing a document is all well and good but if you’re just going to sit and wait to see if the financial strain can be picked up by the private sector first then it’s a bit pointless

Er... what does this mean?

'I can confirm that the US have sole and exclusive rights to p140, informed by Immunopharma.'

Do you mean AVION has sole and exclusive rights to P140 IN the US and that this covers every potential autoimmune disease that P140 can treat? If so then that's a significantly poorer offering from IMM for any other potential partner. Maybe a major pharma will make an offer that also buys out Avion's interests. As I said before I can easily imagine this complication being the reason for the delay in any possible deal.

Wretched pop up ads are worse than ever on this site. Obvs yet another slew of advertising on LSE making them more dosh but making the site a real pain to use, especially when out and on the move.

Interesting post. When you say 'Expected Deal Terms'

'Ex-US rights could fetch $200-500M+ upfront/milestones + double-digit royalties (vs. Avion’s US $70M/17%), boosted by broad IP (20-year exclusivity, diagnostics), differentiating from crowded biologics in $100B+ market, with 2026 close anticipated.'

Is that just for Lupuzor or all of the P140 platform across all potential autoimmune conditions?

Lol so much for the likes of Nvidia being interested.

Think people are finally cottoning on to the fact this is a dud. The directors are taking great salaries for doing nothing.

'THE CHINESE OR THE JAPANESE WON'T.'

True enough Professor and I think that's a genuine possibility. Which are the major pharmas from that part of the world? And do they appear in any lists of the 'top ten' pharma.

Hamila, can't say I disagree with anything you've written there. It would be sh.tty of big pharma to 'bury' P140 but it's a disruptor if we believe what has been said about it. One would hope one of the big top ten pharma would see the potential and have enough financial clout to buyout the whole thing, including Avion but that looks increasingly unlikely at this point.

It's also possible that to save face Tim gets at least one smaller deal over the line in the New Year. What constitutes the New Year? Just January? Jan/Feb? Q1? Who knows. Conveniently opaque and buys Tim time.

Bid moved down to 5.9 now. The drop is now gaining pace. It's sad to see so many let down by the CEO's antics and foolish interviews. Oh well, he'll be fine with his half a million quid from IMM and Incanthera a year

Of course it's not but Tim hasn't bothered to remind anyone of the Avion involvement or their rights. I suspect Avion are the reason a deal wasn't sealed more quickly and by the end of 2025. Any deal is going to be much more difficult to settle with the US market off limits for a chunk of what P140 can do there. I also expect bog pharma to walk away if Avion won't play ball. They know IMM doesn't have anything like enough money or financial backing to get the final phase trials done and get P140 to market and there is also the view point that , if P140 is truly ground breaking and so amazing, that big pharma might see it as more of a threat and prefer to bury it. Avion might actually end up scuppering this for Tim and they themselves end up with very little - and ultimately having to fund Phase 3 trial on their own. Tim hasn't been honest with the market and I think that's why there is a sustained sell off. New Year is only a few weeks away and I'm sure most people have the patience to wait for something really worthwhile. So why are so many selling?

And the BID already dropped less than 30mins into trading:

Down another 10% Rookie and I’m the clown? Yeah right. See you at 5p in the New Year.

A far more reasonable and sensible price prediction imv. I too am planning to buy back in but waiting for a lower entry price of hopefully 5p. A small deal announced by Spring 2026 might well see the sp hit 25p - a 5 bagger. Great return. I’ve just got to get over my concerns on the CEO having never delivered anything to date. Surely he can’t have got this so badly wrong? Even though his language and enthusiasm is far more tempered now than back in Sept he is still adamant there will be a partner/licensing deal. Only needs to be something like $150m and the sp would hit 25p. Just gotta time one’s entry. If people decided to hold then I think they’ll still do well come Spring 2026.

If there is anything genuine here then it’s clearly some way off even being presentable - ‘ Alludium is currently onboarding design partners and refining its agent creation and orchestration features in preparation for a broader release.’

No mention of when so it’s as vague as can be. A nothing RNS as I said.